{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'or placebo], the elamipretide pen injector, and needle) as described in the Pharmacy Manual and', 'Instructions for Use (IFU) pamphlet. The dose of elamipretide will be 40 mg administered as a once', 'daily 0.5 mL SC injection with the elamipretide delivery system.', 'Clinical site staff will train subjects (and caregivers if needed) and ensure understanding of proper SC', 'injection technique on Day 1 and use of the elamipretide delivery system. An elamipretide delivery', 'system training kit and checklist will be provided to the clinical site to assist in training. On Day 1', '(and subsequent clinical site visits), IMP will be administered at the clinical site by the subject or', 'trained caregiver. On non-visit days, the subject (or trained caregiver) will administer the IMP via', 'daily SC injections in the abdomen, rotating around the four abdominal quadrants, or other', 'appropriate location (after Investigator consultation with the Sponsor). The time of the IMP', 'administration should be approximately the same time each day (e.g., early morning, noon, or early', 'afternoon). If a subject is concurrently receiving another SC therapy, unique locations for injections', 'for the IMP, independent from the location of the concomitant therapy injections, should be used.', 'Reference therapy, dosage and mode of administration:', 'The placebo for this trial will be composed of sodium chloride, phosphate buffer, and benzyl alcohol', 'similar to excipients used to manufacture the investigational drug but without the active drug', 'substance. The placebo will be handled and administered identically to active drug.', 'Duration of Trial: Up to 176 weeks', 'This trial is designed with 2 parts, PART 1 and PART 2.', 'PART 1: Up to 32 weeks', 'Screening Period: 7 to 28 days', 'Treatment Period: 24 weeks', 'PART 1 Follow-Up Period: 4 weeks (for subjects not continuing into PART 2). Subjects', 'continuing into PART 2 will not participate in the PART 1 Follow-Up Period.', 'PART 2: Up to 148 weeks', 'Treatment Period: Up to 144 weeks', 'PART 2 Follow-Up Period: 4 weeks', 'Criteria for evaluation:', 'Efficacy:', 'Efficacy will only be assessed for PART 1.', 'Primary Endpoints', 'Distance walked (meters) during the 6MWT', 'Total Fatigue score on the PMMSA', 'Secondary Endpoints', 'Fatigue During Activities score on the PMMSA', 'Neuro-QoL Fatigue Short Form score', 'Most bothersome symptom score on the PMMSA', 'Neuro-QoL Fatigue activities of daily living (specific items from the Neuro-QoL Item', 'Bank)', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '10']['SPIMM-301 Version 4.0', '15 June 2018', 'Exploratory Endpoints', 'Individual symptom scores on the PMMSA', 'Alternate version of the PMMSA Total Fatigue Score', 'Individual item scores on the Neuro-QoL Fatigue', 'EQ-5D-5L scores', 'Patient Global Impression (PGI) Scales', '- PGI of Symptom scores', '- PGI of Change scores', 'Clinician Global Impression (CGI) Scales', '- CGI of Symptom scores', '-', 'CGI of Change scores', 'Pharmacokinetic (PK) Endpoints', 'PK parameters', 'Safety', 'For both PART 1 and PART 2, safety will be assessed through collection of the following data:', 'Adverse Events (AEs)/Adverse Device Effects (ADEs)', 'Vital Signs', 'Electrocardiograms (ECGs)', 'Clinical laboratory evaluations', 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'Statistical methods:', 'Sample Size:', 'A sample size of 202 subjects (101 per treatment arm) provides 90% power to detect a 30-meter', 'difference between treatment groups in the 6MWT and also 90% power to detect a one unit difference', 'in the PMMSA Total Fatigue Score, assuming standard deviations of 60 meters for 6MWT and 2', 'units for the PMMSA Total Fatigue Score, at an alpha-level of 0.025. The two-sided alpha-level of', '0.025 is to account for a possible multiplicity adjustment for the primary endpoint family.', 'General Considerations', 'Data will be tabulated (by treatment group) using descriptive statistics (number of subjects, mean,', 'median, standard deviation, minima, and maxima) for continuous variables and using frequencies and', 'percentages for discrete variables. Inferential statistics will be presented where specified. A', 'comprehensive statistical analysis plan (SAP) will be written and approved prior to database lock.', 'This SAP will detail how missing values are to be handled, windows for trial visits, and how other', 'analysis considerations will be addressed.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '11']\n\n###\n\n", "completion": "END"}